• Fred R Hirsch, Kenichi Suda, Jacinta Wiens, and Paul A Bunn.
• Department of Medicine, Division of Medical Oncology and Department of Pathology, University of Colorado Cancer Center, Aurora, CO, USA; International Association for the Study of Lung Cancer, Aurora, CO, USA. Electronic address: fred.hirsch@ucdenver.edu.
• Lancet. 2016 Sep 3; 388 (10048): 1012-24.

AbstractTargeted therapies are substantially changing the management of lung cancers. These treatments include drugs that target driver mutations, those that target presumed important molecules in cancer cell proliferation and survival, and those that inhibit immune checkpoint molecules. This area of research progresses day by day, with novel target discoveries, novel drug development, and use of novel combination treatments. Researchers and clinicians have also extensively investigated the predictive biomarkers and the molecular mechanisms underlying inherent or acquired resistance to these targeted therapies. We review recent progress in the development of targeted treatments for patients with advanced non-small-cell lung cancer, especially focusing on data from published clinical trials.Copyright © 2016 Elsevier Ltd. All rights reserved.

24 keywords...

hide…